Brief: Can-Fite Biopharma Says To Initiate Phase Iib Nash Study With Its Drug Candidate Namodenoson

Can Fite Biopharma

02/06/2021 12:36

June 2 (Reuters) - Can Fite Biopharma Ltd  CANF.TA :
    * CAN-FITE TO INITIATE PHASE IIB NASH STUDY WITH ITS DRUG
CANDIDATE NAMODENOSON
    * CAN FITE BIOPHARMA LTD - A PRIOR PHASE IIA CLINICAL TRIAL
HAS
BEEN SUCCESSFULLY CONCLUDED AND MET STUDY END POINTS
    * CAN FITE BIOPHARMA LTD - EXPECTS TO COMMENCE ENROLLMENT IN
Q3
2021, AHEAD OF PRIOR EXPECTED START DATE OF Q4 2021

Source text for Eikon:  ID:nBwbrBl9Sa 
Further company coverage:  CANF.TA 

 ((reuters.briefs@thomsonreuters.com;))